Zoledronic acid and clinical fractures and mortality after hip fracture.

ABSTRACT:

Background

Mortality is increased after a hip fracture, and strategies that improve outcomes are needed.

Methods

In this randomized, double-blind, placebo-controlled trial, 1065 patients were assigned to receive yearly intravenous zoledronic acid (at a dose of 5 mg), and 1062 patients were assigned to receive placebo. The infusions were first administered within 90 days after surgical repair of a hip fracture. All patients (mean age, 74.5 years) received supplemental vitamin D and calcium. The median follow-up was 1.9 years. The primary end point was a new clinical fracture.

Results

The rates of any new clinical fracture were 8.6% in the zoledronic acid group and 13.9% in the placebo group, a 35% risk reduction with zoledronic acid (P=0.001); the respective rates of a

SUBMITTER: Lyles KW 

PROVIDER: S-EPMC2324066 | biostudies-literature | 2007 Nov

REPOSITORIES: biostudies-literature